{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:08:56Z","timestamp":1784696936881,"version":"3.55.0"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009750","name":"Familjen Kamprads Stiftelse","doi-asserted-by":"publisher","award":["20210167"],"award-info":[{"award-number":["20210167"]}],"id":[{"id":"10.13039\/501100009750","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Antipsychotic drugs (APD) are commonly prescribed to people living with dementia (PwD) to manage behavioral and psychological symptoms of dementia (BPSD), despite well-documented safety concerns. International guidelines recommend non-pharmacological interventions as first-line treatment, yet APDs remain widely used. This systematic review and meta-analysis synthesize current evidence on the consequences of APD use in PwD. Following PRISMA guidelines, we conducted a comprehensive search of PubMed, EMBASE, Cochrane Library, and Web of Science for studies published between January 2010 and August 2024. The protocol was registered in PROSPERO on 25 March 2022 (CRD42022312570). Eligible studies included observational and interventional designs reporting APD use in PwD. Risk of bias was assessed using the Cochrane tool for randomized trials and the Newcastle-Ottawa Scale for observational studies. Hazard ratios (HRs) were pooled using a random-effects meta-analysis. Subgroup analyses were performed by APD type (typical vs. atypical), study design, risk of bias, and patient setting. The certainty of the evidence was evaluated using GRADE. Forty-five studies comprising two million participants were included. Twenty-five studies reported mortality outcomes. Meta-analysis showed APD use was associated with a significantly increased mortality risk (pooled HR = 1.32; 95% CI 1.12, 1.56), with considerable heterogeneity (I2 = 98.86%). Subgroup analysis indicated similar risk elevation for both typical and atypical APDs and higher hazards among community-dwelling individuals. Evidence for other adverse outcomes, such as stroke, pneumonia, hip fractures, and hospitalization, was limited and heterogeneous, though several individual studies indicated elevated risks. Meta-analysis of cerebrovascular events showed an attenuated but non-significant association (pooled HR = 1.77; 95% CI 0.92-3.42). Conclusion: APD use in PwD is consistently associated with increased mortality and may even elevate risks for serious non-fatal events. These findings emphasize the necessity of cautious prescribing, regular medication review and close monitoring for PWD. Future research can explore drug-specific effects, dose-response relationships, and long-term outcomes, particularly in low-resource settings.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD42022312570.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1817609","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:54:25Z","timestamp":1778219665000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The consequences of antipsychotic medication use for people living with dementia: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Poe Eindra","family":"Thant","sequence":"first","affiliation":[{"name":"Health Economics Unit, Department of Clinical Science (Malm\u00f6), Lund University","place":["Lund, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Zenker","sequence":"additional","affiliation":[{"name":"Health Economics Unit, Department of Clinical Science (Malm\u00f6), Lund University","place":["Lund, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Jarl","sequence":"additional","affiliation":[{"name":"Health Economics Unit, Department of Clinical Science (Malm\u00f6), Lund University","place":["Lund, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf-G\u00f6ran","family":"Gerdtham","sequence":"additional","affiliation":[{"name":"Health Economics Unit, Department of Clinical Science (Malm\u00f6), Lund University","place":["Lund, Sweden"]},{"name":"Department of Economics, Lund University","place":["Lund, Sweden"]},{"name":"Centre for Economic Demography, Lund University","place":["Lund, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Lenander","sequence":"additional","affiliation":[{"name":"Center for Primary Health Care Research, Department of Clinical Sciences Malm\u00f6, Lund University","place":["Malm\u00f6, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Persson","sequence":"additional","affiliation":[{"name":"Health Economics Unit, Department of Clinical Science (Malm\u00f6), Lund University","place":["Lund, Sweden"]},{"name":"The Swedish Institute for Health Economics","place":["Lund, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjib","family":"Saha","sequence":"additional","affiliation":[{"name":"Health Economics Unit, Department of Clinical Science (Malm\u00f6), Lund University","place":["Lund, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"B1","unstructured":"Dementia\n          \n          2022"},{"key":"B2","unstructured":"Key facts (Dementia)\n          \n          2022"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1177\/0706743716673321","article-title":"Antipsychotic use in dementia","volume":"62","author":"Kirkham","year":"2017","journal-title":"Can J Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afaf013","article-title":"Behavioural and psychological symptoms of people with dementia in acute hospital settings: a systematic review and meta-analysis","volume":"54","author":"Anantapong","year":"2025","journal-title":"Age Ageing"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00867-8","article-title":"Efficacy and safety of pharmacotherapy for Alzheimer's disease and for behavioural and psychological symptoms of dementia in older patients with moderate and severe functional impairments: a systematic review of controlled trials","volume":"13","author":"Seibert","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.3630","article-title":"Association of the US Food and Drug Administration antipsychotic drug boxed warning with medication use and health outcomes in elderly patients with dementia","volume":"3","author":"Rubino","year":"2020","journal-title":"JAMA Netw Open"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01465","article-title":"The use of antipsychotic drugs for treating behavioral symptoms in Alzheimer's disease","volume":"10","author":"Calsolaro","year":"2019","journal-title":"Front Pharmacol"},{"key":"B8","doi-asserted-by":"crossref","DOI":"10.1136\/bmjment-2024-301019","article-title":"Efficacy, acceptability and tolerability of second-generation antipsychotics for behavioural and psychological symptoms of dementia: a systematic review and network meta-analysis","volume":"27","author":"Lu","year":"2024","journal-title":"BMJ Ment Health"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/jcp.0000000000001083","article-title":"Mortality risk of atypical antipsychotics for behavioral and psychological symptoms of dementia: a meta-analysis, meta-regression, and trial sequential analysis of randomized controlled trials","volume":"39","author":"Yeh","year":"2019","journal-title":"J Clin Psychopharmacol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2018.12.019","article-title":"Antipsychotic treatment associated with increased mortality risk in patients with dementia. A registry-based observational cohort study","volume":"20","author":"Schwertner","year":"2019","journal-title":"J Am Med Directors Assoc"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2018.04.034","article-title":"All-cause mortality in older adults with affective disorders and dementia under treatment with antipsychotic drugs: a matched-cohort study","volume":"265","author":"Szmulewicz","year":"2018","journal-title":"Psychiatry Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3233\/jad-160671","article-title":"Risk of mortality associated with antipsychotic monotherapy and polypharmacy among community-dwelling persons with Alzheimer\u2019s disease","volume":"56","author":"Koponen","year":"2017","journal-title":"J Alzheimer's Dis"},{"key":"B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40360-017-0142-9","article-title":"Psychotropic drug use and mortality in old people with dementia: investigating sex differences","volume":"18","author":"Br\u00e4nnstr\u00f6m","year":"2017","journal-title":"BMC Pharmacol Toxicol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/0269881118795333","article-title":"Antipsychotic drug use and pneumonia: systematic review and meta-analysis","volume":"32","author":"Dzahini","year":"2018","journal-title":"J Psychopharmacol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s10654-020-00643-2","article-title":"Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes","volume":"36","author":"Mueller","year":"2021","journal-title":"Eur J Epidemiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/01.naj.0001027724.84417.ce","article-title":"Antipsychotics linked to increased risk of adverse outcomes in patients with dementia","volume":"124","author":"Rosenberg","year":"2024","journal-title":"Am J Nurs"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12985","article-title":"Use of antipsychotics and risk of myocardial infarction: a systematic review and meta-analysis","volume":"82","author":"Yu","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076268","article-title":"Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study","volume":"385","author":"Mok","year":"2024","journal-title":"BMJ"},{"key":"B19","article-title":"Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia","volume":"12","author":"Muhlbauer","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd003476.pub2","article-title":"The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease","volume":"2006","author":"Ballard","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2021.48","article-title":"Comparative efficacy, safety, tolerability, and effectiveness of antipsychotics in the treatment of dementia-related psychosis (DRP): a systematic literature review","volume":"8","author":"Yunusa","year":"2021","journal-title":"J Prev Alzheimer's Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.15.1934","article-title":"Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials","volume":"294","author":"Schneider","year":"2005","journal-title":"JAMA"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/s2215-0366(18)30177-9","article-title":"Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials","volume":"5","author":"Schneider-Thoma","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1159\/000540689","article-title":"Risperidone for the treatment of dementia-related psychosis: a systematic review and meta-analysis","volume":"54","author":"Zhou","year":"2025","journal-title":"Dementia Geriatr Cogn Disord"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1007\/s12325-022-02075-8","article-title":"Comparative outcomes of commonly used off-label atypical antipsychotics in the treatment of dementia-related psychosis: a network meta-analysis","volume":"39","author":"Yunusa","year":"2022","journal-title":"Adv Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.0828","article-title":"Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis","volume":"2","author":"Yunusa","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2017.02.020","article-title":"Antipsychotics and the risk of cerebrovascular accident: a systematic review and meta-analysis of observational studies","volume":"18","author":"Hsu","year":"2017","journal-title":"J Am Med Directors Assoc"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2165\/11319120-000000000-00000","article-title":"Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review","volume":"33","author":"Sacchetti","year":"2010","journal-title":"Drug Saf"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2174\/138955708784912175","article-title":"Antipsychotic drugs and cerebrovascular events in elderly patients with dementia: a systematic review","volume":"8","author":"Mazzucco","year":"2008","journal-title":"Mini Rev Med Chem"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2018.06.023","article-title":"Discontinuation of long-term antipsychotic drug use for behavioral and psychological symptoms in older adults aged 65 years and older with dementia","volume":"19","author":"Van Leeuwen","year":"2018","journal-title":"J Am Med Directors Assoc"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200522100-00004","article-title":"Antipsychotics for behavioural and psychological problems in elderly people with dementia: a systematic review of adverse events","volume":"22","author":"van Iersel","year":"2005","journal-title":"Drugs Aging"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2005.12.024","article-title":"Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence","volume":"7","author":"Franco","year":"2006","journal-title":"J Am Med Directors Assoc"},{"key":"B33","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1017\/s1041610212001627","article-title":"Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review","volume":"25","author":"Seitz","year":"2013","journal-title":"Int Psychogeriatrics"},{"key":"B34","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.31222\/osf.io\/v7gm2","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2217\/nmt-2017-0028","article-title":"Parkinson's disease psychosis: presentation, diagnosis and management","volume":"7","author":"Schneider","year":"2017","journal-title":"Neurodegenerative Dis Manage"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B38","unstructured":"Wells\n              G\n            \n          \n          The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses\n          \n          2021"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/mpr.1509","article-title":"Meta-analysis of population-based studies comparing risk of cerebrovascular accident associated with first- and second-generation antipsychotic prescribing in dementia","volume":"25","author":"Rao","year":"2016","journal-title":"Int J Methods Psychiatr Res"},{"key":"B40","article-title":"Chapter 10: Analysing data and undertaking meta-analyses","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 63 [Internet]","author":"Jonathan Deeks","year":"2022"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"B42","volume-title":"Review Manager (RevMan) Version 5.4.1 ed","year":"2020"},{"key":"B43","article-title":"Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 63","author":"Sch\u00fcnemann","year":"2022"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2013.06.007","article-title":"Short-and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study","volume":"22","author":"Langballe","year":"2014","journal-title":"Am J Geriatr Psychiatry"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061771","article-title":"Population-based 5-year follow-up study in Taiwan of dementia and risk of stroke","volume":"8","author":"Liu","year":"2013","journal-title":"PloS One"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.12081046","article-title":"The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer\u2019s disease","volume":"170","author":"Lopez","year":"2013","journal-title":"Am J Psychiatry"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/gps.3858","article-title":"The impact of antipsychotics and neuropsychiatric symptoms on the quality of life of people with dementia living in nursing homes","volume":"28","author":"van de Ven\u2010Vakhteeva","year":"2013","journal-title":"Int J Geriatr Psychiatry"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2015.08.014","article-title":"Increased all-cause mortality with use of psychotropic medication in dementia patients and controls: a population-based register study","volume":"25","author":"Jennum","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2009.10.001","article-title":"Antipsychotic use and the risk of hip fracture among older adults afflicted with dementia","volume":"11","author":"Jalbert","year":"2010","journal-title":"J Am Med Directors Assoc"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2011.03479.x","article-title":"Risk of cerebrovascular accident associated with use of antipsychotics: population\u2010based case\u2013control study","volume":"59","author":"Laredo","year":"2011","journal-title":"J Am Geriatr Soc"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1159\/000435889","article-title":"Low-dose atypical antipsychotic risperidone improves the 5-year outcome in Alzheimer's disease patients with sleep disturbances","volume":"96","author":"Yin","year":"2015","journal-title":"Pharmacology"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.08121844","article-title":"Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD","volume":"168","author":"Vigen","year":"2011","journal-title":"Am J Psychiatry"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s41999-023-00910-x","article-title":"Long-term antipsychotic use, orthostatic hypotension and falls in older adults with Alzheimer's disease","volume":"15","author":"Dyer","year":"2024","journal-title":"Eur Geriatr Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2020.03.028","article-title":"The negative impact of psychotropic drug use on quality of life in nursing home patients at different stages of dementia: cross-sectional analyses from the COSMOS Trial","volume":"21","author":"Ito","year":"2020","journal-title":"J Am Med Directors Assoc"},{"key":"B55","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1177\/07334648211023678","article-title":"Potential side effects and adverse events of antipsychotic use for residents with dementia in assisted living: implications for prescribers, staff, and families","volume":"41","author":"Beeber","year":"2022","journal-title":"J Appl Gerontol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1177\/1060028019866927","article-title":"Emergency department visits for psychotropic-related adverse drug events in older adults with Alzheimer disease, 2013-2014","volume":"53","author":"Sepassi","year":"2019","journal-title":"Ann Pharmacother"},{"key":"B57","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s40120-016-0060-6","article-title":"Risk of adverse outcomes for older people with dementia prescribed antipsychotic medication: a population based e-cohort study","volume":"6","author":"Dennis","year":"2017","journal-title":"Neurol Ther"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-022-00991-6","article-title":"Hallucinations, antipsychotic use, and mortality in older adults with dementia: retrospective cohort study of two Medicare-linked national health surveys","volume":"39","author":"Hamedani","year":"2022","journal-title":"Drugs Aging"},{"key":"B59","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s40520-020-01518-y","article-title":"Initiation of antipsychotics after moving to residential aged care facilities and mortality: a national cohort study","volume":"33","author":"Harrison","year":"2021","journal-title":"Aging Clin Exp Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1159\/000326213","article-title":"Association between prescription of conventional or atypical antipsychotic drugs and mortality in older persons with Alzheimer\u2019s disease","volume":"31","author":"Musicco","year":"2011","journal-title":"Dementia Geriatr Cogn Disord"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glx239","article-title":"The impact of antipsychotic drugs on long-term care, nursing home admission, and death in dementia patients","volume":"73","author":"Nerius","year":"2018","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.11030347","article-title":"Risk of mortality among individual antipsychotics in patients with dementia","volume":"169","author":"Kales","year":"2012","journal-title":"Am J Psychiatry"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.3018","article-title":"Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm","volume":"72","author":"Maust","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"B64","doi-asserted-by":"publisher","first-page":"298","DOI":"10.5498\/wjp.v12.i2.298","article-title":"Associated mortality risk of atypical antipsychotic medication in individuals with dementia","volume":"12","author":"Phiri","year":"2022","journal-title":"World J Psychiatry"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2010.02873.x","article-title":"Are all commonly prescribed antipsychotics associated with greater mortality in elderly male veterans with dementia","volume":"58","author":"Rossom","year":"2010","journal-title":"J Am Geriatr Soc"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.14111","article-title":"Mortality risk of antipsychotic dose and duration in nursing home residents with chronic or acute indications","volume":"64","author":"Simoni\u2010Wastila","year":"2016","journal-title":"J Am Geriatr Soc"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glz045","article-title":"Association between antipsychotics and all-cause mortality among community-dwelling older adults","volume":"74","author":"Kheirbek","year":"2019","journal-title":"J Gerontol: Ser A"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/gps.5587","article-title":"Risk of hospitalization and hip fracture associated with psychotropic polypharmacy in patients with dementia: a nationwide register\u2010based study","author":"Zakarias","year":"2021","journal-title":"Int J Geriatr Psychiatry"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-024-01134-9","article-title":"The relationship between antipsychotics, cognitive enhancers, and major adverse cardiovascular\/cerebrovascular events (MACCE) in older adults with behavioral and psychological symptoms of dementia","volume":"41","author":"DeMercy","year":"2024","journal-title":"Drugs Aging"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/pnp.482","article-title":"Association between antipsychotics and adverse outcomes in dementia","volume":"21","author":"Bangash","year":"2017","journal-title":"Prog Neurol Psychiatry"},{"key":"B71","doi-asserted-by":"crossref","DOI":"10.1111\/jgs.17623","article-title":"Effect of antipsychotics on mortality risk in patients with dementia with and without comorbidities","volume":"70","author":"Norgaard","year":"2022","journal-title":"J Am Geriatr Soc"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2019.07.009","article-title":"Accumulation of hospital days among antipsychotic initiators with Alzheimer's disease","volume":"20","author":"Koponen","year":"2019","journal-title":"J Am Med Directors Assoc"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2021.09.036","article-title":"Antipsychotic use and risk of stroke among community-dwelling people with Alzheimer's disease","volume":"23","author":"Koponen","year":"2022","journal-title":"J Am Med Directors Assoc"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.15m10458","article-title":"Antipsychotic use and the risk of hip fracture among community-dwelling persons with Alzheimer's disease","volume":"78","author":"Koponen","year":"2017","journal-title":"J Clin Psychiatry"},{"key":"B75","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/jgs.16275","article-title":"The risk of head injuries associated with antipsychotic use among persons with Alzheimer's disease","volume":"68","author":"Tapiainen","year":"2020","journal-title":"J Am Geriatr Soc"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.2174\/156720512803569037","article-title":"Antipsychotic use and mortality risk in community-dwelling Alzheimer\u2019s disease patients: evidence for a role of dementia severity","volume":"9","author":"Virginie","year":"2012","journal-title":"Curr Alzheimer Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1177\/0269881118780016","article-title":"The use of antipsychotics is associated with lower mortality in patients with Alzheimer\u2019s disease: a nationwide population-based nested case-control study in Taiwan","volume":"32","author":"Chu","year":"2018","journal-title":"J Psychopharmacol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12614","article-title":"Cumulative dosages of antipsychotic drugs are associated with increased mortality rate in patients with Alzheimer's dementia","volume":"134","author":"Nielsen","year":"2016","journal-title":"Acta Psychiatrica Scand"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2016.03.006","article-title":"Mortality risk in current and new antipsychotic Alzheimer's disease users: large scale Japanese study","volume":"12","author":"Arai","year":"2016","journal-title":"Alzheimer's Dementia"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.06.004","article-title":"Antipsychotic use and risk of hospitalization or death due to pneumonia in persons with and those without Alzheimer disease","volume":"150","author":"Tolppanen","year":"2016","journal-title":"Chest"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.17m11595","article-title":"Effects of antipsychotics on secular mortality trends in patients with Alzheimer's disease","volume":"79","author":"Nielsen","year":"2018","journal-title":"J Clin Psychiatry"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1002\/gps.4101","article-title":"Associations between risk of mortality and atypical antipsychotic use in vascular dementia: a clinical cohort study","volume":"29","author":"Sultana","year":"2014","journal-title":"Int J Geriatr Psychiatry"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1002\/gps.2347","article-title":"Antipsychotics and risk of cerebrovascular events in treatment of behavioural and psychological symptoms of dementia in Hong Kong: a hospital\u2010based, retrospective, cohort study","volume":"25","author":"Chan","year":"2010","journal-title":"Int J Geriatr Psychiatry: A J Psychiatry Late Life Allied Sci"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.695315","article-title":"Potentially inappropriate prescriptions of antipsychotics for patients with dementia","volume":"12","author":"MaChado-Duque","year":"2021","journal-title":"Front Pharmacol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5346","article-title":"Drug exposure misclassification in pharmacoepidemiology: sources and relative impact","volume":"30","author":"Hempenius","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1817609\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:54:30Z","timestamp":1778219670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1817609\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":85,"alternative-id":["10.3389\/fpsyt.2026.1817609"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1817609","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"article-number":"1817609"}}